Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue 5, 2002, Pages 464-470

  Cardiello, Peter G ^a   Van Heeswijk, Rolf P ^a   Hassink, Elly A ^a   Srasuebkul, Preeyaporn ^a   Mahanontharit, Apicha ^a   Samor, Tarika M ^a   Worarien, Wassana ^a   Beijnen, Jos H ^a   Hoetelmans, Richard M ^a   Ruxrungtham, Kiat ^a   Cooper, David A ^a   Lange, Joep M ^a   Phanuphak, Praphan ^a  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Asia; Immune reconstitution; Pharmacokinetics drug interactions; Protease inhibitors; Ritonavir; Saquinavir

Indexed keywords

DIDANOSINE; GELATIN; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; VIRUS LOAD;

EID: 0036235089     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200204150-00006     Document Type: Article

References (17)

1. Antiretroviral therapy in adults.i Updated recommendations of the International AIDS Society-U.S.A. Panel
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
3. Adverse effects of antiretroviral therapy
4. Determinants of heterogenous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study
5. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
6. Once-a-day treatment for HIV infection: Final 48-week results
7. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults
8. A randomized, double blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (Study HIV-NAT 001)
9. Steady-state pharmacokinetics (PK) of saquinavir (SQV) with and without two doses of itraconazole in HIV-1+Thai patients: HIV NAT 001.2 Substudy
10. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection
11. Plasma concentrations of saquinavir determine HIV-1 RNA response over a 48-week period
12. The role of therapeutic drug monitoring in treatment of HIV infection
13. Differences in intracellular drug accumulation between protease inhibitors
14. Pharmacokinetic variability caused by gender: Do women have higher indinavir exposure than men?
15. The safety and pharmacokinetics (PK) of nelfinavir (NFV) in a dose-escalating study in HIV-1-exposed newborn infants: HIV-NAT 007
16. max) predicts CD4+ response in persons with highly suppressed HIV RNA
17. Prevalence and predictive value of intermittent viremia with combination HIV therapy